Circulatory support devices: Fundamental aspects and clinical management of bleeding and thrombosis

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 10, 2015, Pages 1757-1767

  Susen, S ^a,b   Rauch, A ^a,b   Van Belle, E ^a,b   Vincentelli, A ^a,b   Lenting, P J ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c Dept Environ Med Natl Inst Publ HIth   (Norway)

Author keywords

Bleeding; Heart failure; Thrombosis; Ventricular assist device; Von Willebrand factor

Indexed keywords

ANTICOAGULATION; ARTERY CATHETERIZATION; ASSISTED CIRCULATION; ASSISTED VENTILATION; BLEEDING; CARDIOGENIC SHOCK; CLINICAL PRACTICE; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; HEART FAILURE; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; THROMBOSIS; TREATMENT CONTRAINDICATION; VENTRICULAR ASSIST DEVICE; ADVERSE EFFECTS; ANIMAL; BLOOD; BLOOD CLOTTING; DECISION SUPPORT SYSTEM; DRUG EFFECTS; HEART ASSIST DEVICE; HEART LEFT VENTRICLE FUNCTION; HEMORRHAGE; MORTALITY; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ANTICOAGULANT AGENT;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DECISION SUPPORT TECHNIQUES; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HEMORRHAGE; HUMANS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84942870701     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13120     Document Type: Review

References (85)

1. Combes A, Bacchetta M, Brodie D, Muller T, Pellegrino V. Extracorporeal membrane oxygenation for respiratory failure in adults. Curr Opin Crit Care 2012; 18: 99-104.
2. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Miller MA, Timothy Baldwin J, Young JB. Sixth INTERMACS annual report: a 10, 000-patient database. J Heart Lung Transplant 2014; 33: 555-64.
3. Rousse N, Juthier F, Pincon C, Hysi I, Banfi C, Robin E, Fayad G, Jegou B, Prat A, Vincentelli A. ECMO as a bridge to decision: recovery, VAD, or heart transplantation? Int J Cardiol 2015; 187: 620-7.
4. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, Conte JV, Naka Y, Mancini D, Delgado RM, MacGillivray TE, Farrar DJ, Frazier OH. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357: 885-96.
5. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241-51.
6. McIlvennan CK, Magid KH, Ambardekar AV, Thompson JS, Matlock DD, Allen LA. Clinical outcomes after continuous-flow left ventricular assist device: a systematic review. Circ Heart Fail 2014; 7: 1003-13.
7. Hasin T, Marmor Y, Kremers W, Topilsky Y, Severson CJ, Schirger JA, Boilson BA, Clavell AL, Rodeheffer RJ, Frantz RP, Edwards BS, Pereira NL, Stulak JM, Joyce L, Daly R, Park SJ, Kushwaha SS. Readmissions after implantation of axial flow left ventricular assist device. J Am Coll Cardiol 2013; 61: 153-63.
8. McMurray JJ, Petrie MC, Murdoch DR, Davie AP.Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998; 19 Suppl. P: P9-16.
9. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068-72.
10. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345: 1435-43.
11. Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Goldfarb SB, Levvey BJ, Meiser B, Yusen RD, Stehlik J. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report - 2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33: 996-1008.
12. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Timothy Baldwin J, Young JB. Fifth INTERMACS annual report: risk factor analysis from more than 6, 000 mechanical circulatory support patients. J Heart Lung Transplant 2013; 32: 141-56.
13. Grady KL, Naftel DC, Myers S, Dew MA, Weidner G, Spertus JA, Idrissi K, Lee HB, McGee EC, Kirklin JK. Change in health-related quality of life from before to after destination therapy mechanical circulatory support is similar for older and younger patients: analyses from INTERMACS. J Heart Lung Transplant 2015; 34: 213-21.
14. Khazanie P, Hammill BG, Patel CB, Eapen ZJ, Peterson ED, Rogers JG, Milano CA, Curtis LH, Hernandez AF. Trends in the use and outcomes of ventricular assist devices among medicare beneficiaries, 2006 through 2011. J Am Coll Cardiol 2014; 63: 1395-404.
15. Uriel N, Han J, Morrison KA, Nahumi N, Yuzefpolskaya M, Garan AR, Duong J, Colombo PC, Takayama H, Thomas S, Naka Y, Jorde UP. Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon. J Heart Lung Transplant 2014; 33: 51-9.
16. Bunte MC, Blackstone EH, Thuita L, Fowler J, Joseph L, Ozaki A, Starling RC, Smedira NG, Mountis MM. Major bleeding during HeartMate II support. J Am Coll Cardiol 2013; 62: 2188-96.
17. Boyle AJ, Jorde UP, Sun B, Park SJ, Milano CA, Frazier OH, Sundareswaran KS, Farrar DJ, Russell SD. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol 2014; 63: 880-8.
18. Dean D, Kallel F, Ewald GA, Tatooles A, Sheridan BC, Brewer RJ, Caldeira C, Farrar DJ, Akhter SA. Reduction in driveline infection rates: results from the HeartMate II Multicenter Driveline Silicone Skin Interface (SSI) Registry. J Heart Lung Transplant 2015; 34: 781-9.
19. Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, Rame JE, Acker MA, Blackstone EH, Ehrlinger J, Thuita L, Mountis MM, Soltesz EG, Lytle BW, Smedira NG. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 2014; 370: 33-40.
20. Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD, Starling RC, Chen L, Boyle AJ, Chillcott S, Adamson RM, Blood MS, Camacho MT, Idrissi KA, Petty M, Sobieski M, Wright S, Myers TJ, Farrar DJ; HeartMate II Clinical Investigators Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010; 29: S1-39.
21. Boyle AJ, Russell SD, Teuteberg JJ, Slaughter MS, Moazami N, Pagani FD, Frazier OH, Heatley G, Farrar DJ, John R. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant 2009; 28: 881-7.
22. Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL, Stevenson LW, Acker MA, Goldstein DL, Silvestry SC, Milano CA, Timothy Baldwin J, Pinney S, Eduardo Rame J, Miller MA. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant 2014; 33: 12-22.
23. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Ulisney KL, Baldwin JT, Young JB. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant 2011; 30: 115-23.
24. Tsiouris A, Paone G, Nemeh HW, Brewer RJ, Morgan JA. Factors determining post-operative readmissions after left ventricular assist device implantation. J Heart Lung Transplant 2014; 33: 1041-7.
25. Crow S, John R, Boyle A, Shumway S, Liao K, Colvin-Adams M, Toninato C, Missov E, Pritzker M, Martin C, Garry D, Thomas W, Joyce L. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 2009; 137: 208-15.
26. Islam S, Cevik C, Madonna R, Frandah W, Islam E, Islam S, Nugent K. Left ventricular assist devices and gastrointestinal bleeding: a narrative review of case reports and case series. Clin Cardiol 2013; 36: 190-200.
27. Aggarwal A, Pant R, Kumar S, Sharma P, Gallagher C, Tatooles AJ, Pappas PS, Bhat G. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thorac Surg 2012; 93: 1534-40.
28. Lauten A, Engstrom AE, Jung C, Empen K, Erne P, Cook S, Windecker S, Bergmann MW, Klingenberg R, Luscher TF, Haude M, Rulands D, Butter C, Ullman B, Hellgren L, Modena MG, Pedrazzini G, Henriques JP, Figulla HR, Ferrari M. Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail 2013; 6: 23-30.
29. Manzo-Silberman S, Fichet J, Mathonnet A, Varenne O, Ricome S, Chaib A, Zuber B, Spaulding C, Cariou A. Percutaneous left ventricular assistance in post cardiac arrest shock: comparison of intra aortic blood pump and IMPELLA Recover LP2.5. Resuscitation. 2013; 84: 609-15.
30. Goldstein DJ, John R, Salerno C, Silvestry S, Moazami N, Horstmanshof D, Adamson R, Boyle A, Zucker M, Rogers J, Russell S, Long J, Pagani F, Jorde U. Algorithm for the diagnosis and management of suspected pump thrombus. J Heart Lung Transplant 2013; 32: 667-70.
31. Blitz A. Pump thrombosis - a riddle wrapped in a mystery inside an enigma. Ann Cardiothorac Surg. 2014; 3: 450-71.
32. Frazier OH, Delgado RM 3rd, Kar B, Patel V, Gregoric ID, Myers TJ. First clinical use of the redesigned HeartMate II left ventricular assist system in the United States: a case report. Tex Heart Inst J 2004; 31: 157-9.
33. Najjar SS, Slaughter MS, Pagani FD, Starling RC, McGee EC, Eckman P, Tatooles AJ, Moazami N, Kormos RL, Hathaway DR, Najarian KB, Bhat G, Aaronson KD, Boyce SW. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2014; 33: 23-34.
34. Birschmann I, Dittrich M, Eller T, Wiegmann B, Reininger AJ, Budde U, Struber M. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices. J Heart Lung Transplant 2014; 33: 80-7.
35. Slaughter MS, Sobieski MA 2nd, Graham JD, Pappas PS, Tatooles AJ, Koenig SC. Platelet activation in heart failure patients supported by the HeartMate II ventricular assist device. Int J Artif Organs 2011; 34: 461-8.
36. Baumann Kreuziger LM, Kim B, Wieselthaler GM. Antithrombotic therapy for left ventricular assist devices in adults: a systematic review. J Thromb Haemost 2015; 13: 946-55.
37. Meyer AL, Malehsa D, Budde U, Bara C, Haverich A, Strueber M. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail 2014; 2: 141-5.
38. Van Belle E, Rauch A, Vincentelli A, Jeanpierre E, Legendre P, Juthier F, Hurt C, Banfi C, Rousse N, Godier A, Caron C, Elkalioubie A, Corseaux D, Dupont A, Zawadzki C, Delhaye C, Mouquet F, Schurtz G, Deplanque D, Chinetti G, et al. Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. Circ Res 2015; 116: 1193-201.
39. Stulak JM, Deo S, Schirger J, Aaronson KD, Park SJ, Joyce LD, Daly RC, Pagani FD. Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation. Ann Thorac Surg 2013; 96: 2161-7.
40. Saeed O, Jermyn R, Kargoli F, Madan S, Mannem S, Gunda S, Nucci C, Farooqui S, Hassan S, McLarty A, Bloom M, Zolty R, Shin J, D'Alessandro D, Goldstein DJ, Patel SR. Blood pressure and adverse events during continuous flow left ventricular assist device support. Circ Heart Fail 2015; 8: 551-6.
41. Salamonsen RF, Mason DG, Ayre PJ. Response of rotary blood pumps to changes in preload and afterload at a fixed speed setting are unphysiological when compared with the natural heart. Artif Organs 2011; 35: E47-53.
42. Warkentin TE, Greinacher A, Koster A. Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required? Ann Thorac Surg 2009; 87: 1633-40.
43. Adatya S, Uriel N, Yarmohammadi H, Holley CT, Feng A, Roy SS, Reding MT, John R, Eckman P, Zantek ND. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support. JACC Heart Fail 2015; 3: 314-22.
44. Uriel N, Pak SW, Jorde UP, Jude B, Susen S, Vincentelli A, Ennezat PV, Cappleman S, Naka Y, Mancini D. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010; 56: 1207-13.
45. Schaffer JM, Arnaoutakis GJ, Allen JG, Weiss ES, Patel ND, Russell SD, Shah AS, Conte JV. Bleeding complications and blood product utilization with left ventricular assist device implantation. Ann Thorac Surg 2011; 91: 740-7.
46. Slaughter MS, Naka Y, John R, Boyle A, Conte JV, Russell SD, Aaronson KD, Sundareswaran KS, Farrar DJ, Pagani FD. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transplant 2010; 29: 616-24.
47. Litzler PY, Smail H, Barbay V, Nafeh-Bizet C, Bouchart F, Baste JM, Abriou C, Bessou JP. Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience. Eur J Cardiothorac Surg 2014; 45: 55-9.
48. Upshaw JE. Single center experience of thrombosis in continuous flow left ventricular devices; diagnosis, management and outcomes. Circulation 2012; 126: A16420.
49. Holmes DR Jr, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 2009; 54: 95-109.
50. Paikin JS, Wright DS, Eikelboom JW. Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Blood Rev 2011; 25: 123-9.
51. Geisen U, Heilmann C, Beyersdorf F, Benk C, Berchtold-Herz M, Schlensak C, Budde U, Zieger B. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 2008; 33: 679-84.
52. Heilmann C, Geisen U, Beyersdorf F, Nakamura L, Trummer G, Berchtold-Herz M, Schlensak C, Zieger B. Acquired Von Willebrand syndrome is an early-onset problem in ventricular assist device patients. Eur J Cardiothorac Surg 2011; 40: 1328-33.
53. Goda M, Jacobs S, Rega F, Peerlinck K, Jacquemin M, Droogne W, Vanhaecke J, Van Cleemput J, Van den Bossche K, Meyns B. Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump. J Heart Lung Transplant 2013; 32: 539-45.
54. Heilmann C, Geisen U, Beyersdorf F, Nakamura L, Benk C, Trummer G, Berchtold-Herz M, Schlensak C, Zieger B. Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS). Intensive Care Med 2012; 38: 62-8.
55. Davis ME, Haglund NA, Tricarico NM, Keebler ME, Maltais S. Development of acquired von Willebrand syndrome during short-term micro axial pump support: implications for bleeding in a patient bridged to a long-term continuous-flow left ventricular assist device. ASAIO J 2014; 60: 355-7.
56. Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, Bauters A, Decoene C, Goudemand J, Prat A, Jude B. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-9.
57. Warkentin TE, Moore JC, Anand SS, Lonn EM, Morgan DG. Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfus Med Rev 2003; 17: 272-86.
58. Blackshear JL, Wysokinska EM, Safford RE, Thomas CS, Shapiro BP, Ung S, Stark ME, Parikh P, Johns GS, Chen D. Shear stress-associated acquired von Willebrand syndrome in patients with mitral regurgitation. J Thromb Haemost 2014; 12: 1966-74.
59. Shimizu M, Masai H, Miwa Y. Occult gastrointestinal bleeding due to acquired von Willebrand syndrome in a patient with hypertrophic obstructive cardiomyopathy. Intern Med 2007; 46: 481-5.
60. Le Tourneau T, Susen S, Caron C, Millaire A, Marechaux S, Polge AS, Vincentelli A, Mouquet F, Ennezat PV, Lamblin N, de Groote P, Van Belle E, Deklunder G, Goudemand J, Bauters C, Jude B. Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction. Circulation 2008; 118: 1550-7.
61. Blackshear JL, Stark ME, Agnew RC, Moussa ID, Safford RE, Shapiro BP, Waldo OA, Chen D. Remission of recurrent gastrointestinal bleeding after septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy-associated acquired von Willebrand syndrome. J Thromb Haemost 2015; 13: 191-6.
62. Springer TA. von Willebrand factor: Jedi knight of the bloodstream. Blood 2014; 124: 1412-25.
63. Pareti FI, Lattuada A, Bressi C, Zanobini M, Sala A, Steffan A, Ruggeri ZM. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000; 102: 1290-5.
64. Meyer AL, Malehsa D, Bara C, Budde U, Slaughter MS, Haverich A, Strueber M. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 2010; 3: 675-81.
65. Rauch A, Legendre P, Christophe OD, Goudemand J, Van Belle E, Vincentelli A, Denis CV, Susen S, Lenting PJ. Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices. Thromb Haemost 2014; 112: 1014-23.
66. Dassanayaka S, Slaughter MS, Bartoli CR. Mechanistic pathway(s) of acquired von Willebrand syndrome with a continuous-flow ventricular assist device: in vitro findings. ASAIO J 2013; 59: 123-9.
67. Fiore M, James C, Mouton C, Calderon J, Barandon L, Ouattara A, Picard F. Assessment of platelet function with light transmission aggregometry in 24 patients supported with a continuous-flow left ventricular assist device: a single-center experience. J Thorac Cardiovasc Surg 2014; 148: 3119-25.
68. Hu J, Mondal NK, Sorensen EN, Cai L, Fang HB, Griffith BP, Wu ZJ. Platelet glycoprotein Ibalpha ectodomain shedding and non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist devices. J Heart Lung Transplant 2014; 33: 71-9.
69. Baghai M, Heilmann C, Beyersdorf F, Nakamura L, Geisen U, Olschewski M, Zieger B. Platelet dysfunction and acquired von Willebrand syndrome in patients with left ventricular assist devices. Eur J Cardiothorac Surg 2015; 48: 421-7.
70. Fressinaud E, Meyer D. International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost 1993; 70: 546.
71. Castaman G, Federici AB, Tosetto A, La Marca S, Stufano F, Mannucci PM, Rodeghiero F. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost 2012; 10: 632-8.
72. Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, Payne EM, Haskard DO, Hughes AD, Cutler DF, Laffan MA, Randi AM. Endothelial von Willebrand factor regulates angiogenesis. Blood 2011; 117: 1071-80.
73. Starke RD, Paschalaki KE, Dyer CE, Harrison-Lavoie KJ, Cutler JA, McKinnon TA, Millar CM, Cutler DF, Laffan MA, Randi AM. Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells. Blood 2013; 121: 2773-84.
74. Baliga RR. From clinical observation to mechanism - Heyde's syndrome. N Engl J Med 2013; 368: 579.
75. Wever-Pinzon O, Selzman CH, Drakos SG, Saidi A, Stoddard GJ, Gilbert EM, Labedi M, Reid BB, Davis ES, Kfoury AG, Li DY, Stehlik J, Bader F. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 2013; 6: 517-26.
76. Jackson CS, Gerson LB. Management of gastrointestinal angiodysplastic lesions (GIADs): a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 474-83.
77. Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, Deng M, Dickstein ML, El-Banayosy A, Elliot T, Goldstein DJ, Grady KL, Jones K, Hryniewicz K, John R, Kaan A, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 2013; 32: 157-87.
78. Jorde UP, Uriel N, Nahumi N, Bejar D, Gonzalez-Costello J, Thomas SS, Han J, Morrison KA, Jones S, Kodali S, Hahn RT, Shames S, Yuzefpolskaya M, Colombo P, Takayama H, Naka Y. Prevalence, significance, and management of aortic insufficiency in continuous flow left ventricular assist device recipients. Circ Heart Fail 2014; 7: 310-19.
79. Stulak JM, Lee D, Haft JW, Romano MA, Cowger JA, Park SJ, Aaronson KD, Pagani FD. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant 2014; 33: 60-4.
80. Cushing M, Kawaguchi K, Friedman KD, Mark T. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. Transfusion 2012; 52: 1535-41.
81. Fischer Q, Huisse MG, Voiriot G, Caron C, Lepage L, Dilly MP, Nataf P, Ajzenberg N, Kirsch M. Von Willebrand factor, a versatile player in gastrointestinal bleeding in left ventricular assist device recipients? Transfusion 2015; 55: 51-4.
82. Mazurier C, Poulle M, Samor B, Hilbert L, Chtourou S. In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang 2004; 86: 100-4.
83. Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007; 5: 1115-24.
84. Hayes HM, Dembo LG, Larbalestier R, O'Driscoll G. Management options to treat gastrointestinal bleeding in patients supported on rotary left ventricular assist devices: a single-center experience. Artif Organs 2010; 34: 703-6.
85. Coutance G, Saplacan V, Belin A, Repesse Y, Buklas D, Massetti M. Octreotide for recurrent intestinal bleeding due to ventricular assist device. Asian Cardiovasc Thorac Ann 2014; 22: 350-2.